Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy()()

por Shahwan, K.T., Kimball, A.B.
Publicado 2016

An assessment of the relative impact of hidradenitis suppurativa, psoriasis, and obesity on quality of life()()

por Storer, M.A., Danesh, M.J., Sandhu, M.E., Pascoe, V., Kimball, A.B.
Publicado 2018

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

por Gordon, KB, Kimball, AB, Chau, D, Viswanathan, HN, Li, J, Revicki, DA, Kricorian, G, Ortmeier, BG
Publicado 2014

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice

por Kimball, A.B., Crowley, J.J., Papp, K., Calimlim, B., Duan, Y., Fleischer, A.B., Sobell, J.
Publicado 2020

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

por Kimball, AB, Leonardi, C, Stahle, M, Gulliver, W, Chevrier, M, Fakharzadeh, S, Goyal, K, Calabro, S, Langholff, W, Menter, A
Publicado 2014

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III stu...

por Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Publicado 2019

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

por Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Publicado 2019

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

por Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Publicado 2018

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled...

por Kimball, A.B., Sobell, J.M., Zouboulis, C.C., Gu, Y., Williams, D.A., Sundaram, M., Teixeira, H.D., Jemec, G.B.E.
Publicado 2015

Unmet clinical needs and burden of disease in hidradenitis suppurativa: real‐world experience from EU5 and US

por Ingram, J.R., Bettoli, V., Espy, J.I., Kokolakis, G., Martorell, A., Villani, A.P., Wallinger, H., Coak, E., Kasparek, T., Muscianisi, E., Richardson, C., Kimball, A.B.
Publicado 2022

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials

por Jemec, G.B.E., Okun, M.M., Forman, S.B., Gulliver, W.P.F., Prens, E.P., Mrowietz, U., Armstrong, A.W., Geng, Z., Gu, Y., Williams, D.A., Teixeira, H.D., Kimball, A.B.
Publicado 2019

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

por Zouboulis, C.C., Bechara, F.G., Dickinson‐Blok, J.L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A.B., Kirby, B., Martorell, A., Podda, M., Prens, E.P., Ring, H.C., Tzellos, T., van der Zee, H.H., van Straalen, K.R., Vossen, A.R.J.V., Jemec, G.B.E.
Publicado 2018